Cognition in Parkinson's Disease

1st Edition, Volume 269 - February 18, 2022
Imprint: Elsevier
Editors: Nandakumar Narayanan, Roger Albin
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 9 0 1 6 4 - 2
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 0 1 6 5 - 9

Cognition in Parkinson's Disease, Volume 269 in the Progress in Brain Research series, highlights new advances in the field, with this new volume presenting interesting c… Read more

Purchase options

World Book Day Celebration!

Save up to 30% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Cognition in Parkinson's Disease, Volume 269 in the Progress in Brain Research series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Cognition in Prodromal Parkinson’s disease, The epidemiology of cognitive function in Parkinson's disease, Real-life consequences of cognitive dysfunction in Parkinson’s disease, Animal models of cognition in Parkinson’s disease, Functional neuroanatomy of cognition in Parkinson’s disease, Neuroimaging approaches to cognition in Parkinson’s disease, Cognitive dysfunction and neuropsychiatric aspects of Parkinson’s disease, Neuropsychology of Parkinson’s disease, Cholinergic Systems, Attentional-Motor Integration, and Cognitive Control in Parkinson Disease, and much more.

Cover
Title page
Table of Contents
Copyright
Contributors
Preface
References
Section 1: Defining the problem
Chapter 1: The epidemiology of cognitive function in Parkinson's disease
Abstract
1: Introduction
2: The epidemiology of Parkinson's disease
3: Definitions of mild cognitive impairment and dementia in Parkinson's disease
4: Comorbid pathology
5: The epidemiology of cognitive change in Parkinson's disease
6: Predictors of cognitive decline in Parkinson's disease
7: Protective factors for cognitive decline in Parkinson's disease
8: The epidemiology of neuropsychiatric features in Parkinson's disease
9: Sequelae of cognitive change
10: Conclusions and future directions
References
Chapter 2: Neuropsychology of Parkinson's disease
1: Introduction
2: Evaluating cognition in PD
3: Tests and testing issues
4: Test interpretation
5: Clinical applications
6: Conclusion
References
Chapter 3: Cognitive dysfunction and neuropsychiatric aspects of Parkinson's disease
Abstract
1: Introduction
2: Depressive disorders
3: Anxiety
4: Psychosis
5: Apathy
6: Impulse-control disorders
7: Conclusions
References
Section 2: Clinical characteristics
Chapter 4: Cognition in prodromal Parkinson's disease
Abstract
1: Introduction
2: How to evaluate cognitive impairment in the prodromal stage of PD?
3: Cognitive profiles and trajectories in prodromal PD
4: When does cognitive worsening occur in prodromal PD?
5: Conclusion and future directions
References
Chapter 5: Real-life consequences of cognitive dysfunction in Parkinson's disease
Abstract
1: Introduction
2: Employment
3: Family and social life
4: Driving
5: Conclusion
References
Chapter 6: Cognitive control in Parkinson's disease
Abstract
1: What is cognitive control?
2: Manifest assessment of cognitive control
3: Manifest deficits in cognitive control in Parkinson's disease
4: Neural systems of cognitive control
5: Salience network deficits underlying cognitive control in Parkinson's disease
6: Dopamine: Motivation and cognitive control
7: Dopamine in Parkinson's disease: Altered motivation and cognitive control
8: Summary
References
Chapter 7: Speech dysfunction, cognition, and Parkinson's disease
Abstract
1: Introduction
2: Linkages between cognition and speech production in Parkinson's disease
3: Overview of communication difficulties in Parkinson's disease
4: Parkinson's disease treatments and speech, language, and communication
5: Summary
References
Section 3: Pathophysiology
Chapter 8: Neuropathological substrates of cognition in Parkinson's disease
Abstract
1: Patterns of cognitive deficits in Parkinson's disease
2: Alpha-synuclein neuropathology in Parkinson's disease cognitive impairment
3: Emerging alpha-synuclein biomarkers and cognition in Parkinson's disease
4: Influence of co-pathologies on cognition in Parkinson's disease
5: In vivo biomarkers of co-pathologies and cognition in PD
6: Conclusion
References
Chapter 9: Genetics of cognitive dysfunction in Parkinson's disease
Abstract
1: Introduction
2: Genetics of PD: What we know (state of the discourse)
3: The study of cognitive dysfunction in genetic PD
4: Review of the literature
5: Polygenic risk scores and genetic variants associated with PD
6: Polygenic risk scores
7: Cognition associated with less common genetic mutations or polymorphisms which convey an elevated risk of PD
8: Conclusion and future directions
References
Chapter 10: Animal models of action control and cognitive dysfunction in Parkinson's disease
Abstract
1: Introduction
2: Animal cognition in action
3: The neural bases of cognitive control
4: Studies in animals relevant to cognitive dysfunction in PD
5: Conclusions
Acknowledgments
References
Chapter 11: Neuroimaging approaches to cognition in Parkinson's disease
Abstract
1: Introduction
2: Neuroimaging of structural brain changes associated with cognition in PD
3: Neuroimaging of functional brain networks associated with cognition in PD
4: Neuroimaging of non-dopaminergic neurotransmitter dysfunction
5: Imaging co-pathologies associated with cognitive impairment in PD
6: Conclusion
References
Section 4: Circuit mechanisms
Chapter 12: Functional neuroanatomy of cognition in Parkinson's disease
Abstract
1: Introduction
2: Frontostriatal circuit
3: Mesocortical circuit
4: Frontoparietal circuit
5: Noradrenergic circuits
6: Conclusion
References
Chapter 13: Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease
Abstract
1: Introduction
2: Deficient functions associated with fronto-striatal circuitry
3: Role of dopamine in fronto-striatal dysfunction
4: Detrimental effects of dopaminergic medication on fronto-striatal function
5: The dopamine denervation hypothesis
6: The double hit hypothesis
7: The dopamine overdose hypothesis
8: Mechanisms of impaired learning and choice with excessive dopamine stimulation
9: From accounts of within-patient variability to between-patient variability in dopamine drug effects
10: Dopaminergic medication effects on risky choice depend on depression history
11: Dopaminergic medication effects on reversal learning depend on depression
12: Dopaminergic medication effects on learning and choice depend on motor phenotype
13: Conclusion
References
Chapter 14: Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease
Abstract
1: Introduction
2: Cholinergic systems organization and functions
3: Tools to study cholinergic systems in humans
4: Cholinergic system changes in PD: Post-mortem studies
5: Cholinergic system changes in PD: Imaging studies and cognitive deficits
6: Cholinergic system changes in PD: Imaging studies and gait-balance deficits
7: Cholinergic system changes in PD: Early compensation: Upregulation?
8: Conclusions
Acknowledgments
References
Chapter 15: Cognition and serotonin in Parkinson's disease
Abstract
1: Neurotransmitter systems of cognition in PD
2: 5-HT in the neuropsychiatric manifestations of PD
3: Clinical trials with serotonergic agents for cognition in PD
4: Concluding remarks
References
Section 5: Towards Therapies
Chapter 16: Caring for patients with cognitive dysfunction, fluctuations and dementia caused by Parkinson's disease
Abstract
1: Prior to diagnoses: PD patients without known cognitive impairment
2: Making the diagnosis: Mild cognitive impairment and dementia
3: After the diagnosis: Caring for Parkinson's disease patients with dementia
4: Complications and progression
5: Future directions
References
Chapter 17: Neuromodulation of cognition in Parkinson's disease
Abstract
1: Introduction
2: Types and targets of neuromodulation used for PD
3: New advances in neuromodulation
4: Conclusion
Funding
References
Chapter 18: The way forward for cognition in Parkinson's disease
Abstract
References

Nandakumar Narayanan

Dr. Nandakumar Narayanan is Associate Professor & Associate Director of the Iowa Neuroscience Institute, University of Iowa. The specific problem of his research is cognitive dysfunction in Parkinsons disease. His current research focuses on the influence of dopamine on prefrontal networks controlling cognitive behaviors such as timing and performance monitoring. His research combines ensemble recording from populations of neurons in awake, behaving animals with specific manipulations using techniques such as optogenetic stimulation, targeted pharmacology, or selective genetic disruption with RNA interference. HIs research hopes to identify new treatment strategies that can be translated to a clinical setting.

Affiliations and expertise

Associate Professor of Neurology, Department of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, USA

Roger Albin

Roger L. Albin, MD, is a professor of neurology and co-director of the Movement Disorders Clinic in the Department of Neurology in the University of Michigan Medical School. In addition, he serves as chief of neuroscience research at the VA Ann Arbor Healthcare System Geriatric Research Education and Clinical Center. Dr. Albin joined the University of Michigan faculty in 1988 as an instructor in the Department of Neurology. He was promoted to assistant professor in 1989; associate professor in 1994; and achieved his current rank of full professor in 2000. After completing his undergraduate degree at Oberlin College in Ohio, Dr. Albin earned his medical degree from the University of Pittsburgh School of Medicine in 1982, and completed his residency at the University of Michigan in 1986. He also completed a movement disorders fellowship in 1988 under Drs. Anne Young and John Penney. His clinical and research interests include the underlying neurobiologic causes of the clinical features of movement disorders, basal ganglia structure and function, Parkinson's disease, Tourette syndrome, dementias, dystonias and Huntington's disease. His laboratory is pursuing work on basic mechanisms of neurodegeneration in Huntington disease using mouse genetic models. Dr. Albin also has participated in neuroprotective clinical trials for both Huntington's disease and Parkinson's disease. The present focus of Dr. Albin's group is uncovering the basis for non-motor (sleep disorders, depression, dementia, autonomic dysfunction) problems in Parkinson's disease. He is very interested in applying positron emission tomography (PET) imaging methods to improve diagnosis of dementing disorders like Alzheimer's disease. The hope is that understanding how specific brain alterations cause specific clinical features will lead to improved treatments. Dr. Albin currently serves as a site investigator for the National Institutes of Health (NIH) Exploratory Trials in Parkinson disease (NET-PD) initiative. His work is supported by grants from the NIH, the Michael J. Fox Foundation and the High Q Foundation. A member of the American Academy of Neurology, the American Association for the Advancement of Science, the American Neurologic Association, and the Society for Neuroscience, Dr. Albin currently serves on the editorial boards of Experimental Neurology, Neurology and Neurobiology of Disease.

Affiliations and expertise

Professor of Neurology, Neuroscience Graduate Program, University of MIchigan, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health